Cataract Surgery: Telling It Like It Is

Cataract Surgery: Telling It Like It Is

Source:

Mandell KJ. New technology showdowns: New drugs and delivery systems. Presented at: Cataract Surgery: Telling It Like It Is. June 9-13, 2021; Amelia Island, Florida.

Disclosures: Mandell reports he is CEO of LayerBio.
June 11, 2021
1 min read
Save

Ketorolac implant has potential to disrupt NSAID delivery in cataract surgery

Source:

Mandell KJ. New technology showdowns: New drugs and delivery systems. Presented at: Cataract Surgery: Telling It Like It Is. June 9-13, 2021; Amelia Island, Florida.

Disclosures: Mandell reports he is CEO of LayerBio.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

AMELIA ISLAND, Fla. — A new intraoperative ketorolac delivery device has the potential to disrupt NSAID delivery in cataract surgery, according to a presenter here.

At Cataract Surgery: Telling It Like It Is, Kenneth J. Mandell, MD, PhD, CEO of LayerBio, shared early clinical results of the OcuRing-K ketorolac device.

The OcuRing-K is a bioerodible steroid-sparing implant that is affixed to the IOL haptic before implantation and elutes ketorolac for 2 weeks to control pain and inflammation following surgery, according to Mandell.

“The OcuRing-K has the potential to expand the NSAID market by avoiding the side effects of topical NSAIDs,” Mandell said.

Mandell shared drawbacks of topical NSAIDs, such as delayed healing, the potential for corneal melts and incompatibility for patients with comorbidities such as diabetes or dry eye disease, which comprises more than 30% of the cataract surgery candidate population.

The OcuRing-K sits inside the eye to avoid topical NSAID side effects, as well as patient compliance issues with controlled drug delivery, he said. The device can be affixed to the haptic of any standard IOL, and no modification of IOL implantation technique is required.

“We’ve done a phase 1 study, and we’ve now extended for more than 12 months,” he said. The company plans to initiate phase 2 studies in 2022.